Millions of Americans take a daily multivitamin expecting it to guard against serious illness, but the largest and most recent body of clinical evidence shows that the habit does little to lower cancer risk or cancer death rates. A systematic review commissioned by the U.S. Preventive Services Task Force, drawing on searches conducted through February 2022, found no meaningful reduction in cancer incidence or mortality among adults who took multivitamin and mineral supplements. Separate analyses tracking nearly 400,000 healthy U.S. adults for more than 20 years reached the same conclusion, and the National Cancer Institute now states plainly that the evidence is insufficient to support multivitamin use for cancer prevention.
Why the multivitamin-cancer question carries fresh weight
The tension here is not academic. Supplement sales in the United States run into the tens of billions of dollars annually, and cancer prevention ranks among the most common reasons consumers cite for taking a daily pill. When federal health agencies and independent reviewers repeatedly find no protective effect, the gap between public behavior and scientific evidence widens. The latest USPSTF-commissioned review, published in JAMA, pooled results from randomized controlled trials and observational studies and concluded that multivitamins did not meaningfully reduce cancer incidence or cancer mortality in generally healthy adults.
One hypothesis worth examining is whether long-term multivitamin users whose diets already meet recommended nutrient levels might still show a modest cancer benefit once researchers control for baseline nutrition. The available trial data, however, does not support that idea. The largest modern U.S. randomized trial on the question, the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), enrolled 21,442 older adults, assigned them to receive either Centrum Silver or placebo, and tracked them for a median of approximately 3.6 years. Total invasive cancer was the primary endpoint, and the trial did not find a clear preventive benefit. Because participants in COSMOS were older adults with generally adequate diets, the results suggest that filling nutritional gaps through a pill does not translate into cancer protection even when the population is well nourished.
Trial and cohort data converge on the same answer
The strength of the current evidence lies in the consistency across study designs. Randomized trials and large observational cohorts, which capture real-world supplement habits over decades, both point in the same direction. The COSMOS trial is one pillar. Another is the French SU.VI.MAX study, a randomized, placebo-controlled trial of daily antioxidant vitamins and minerals that assessed cancer and cardiovascular disease incidence. SU.VI.MAX is commonly included in evidence reviews as an antioxidant-focused multivitamin comparator, and its results contributed to the pooled estimates that informed the USPSTF position.
On the observational side, a National Cancer Institute-led analysis examined nearly 400,000 healthy U.S. adults drawn from three prospective cohorts: NIH-AARP, PLCO, and the Agricultural Health Study. Participants were followed for more than 20 years. The study, published in JAMA Network Open, found no association between regular multivitamin use and a lower risk of death from any cause, including cancer. The NCI summarized the finding in direct language: for healthy adults, taking multivitamins daily is not associated with a lower risk of death. The NCI’s own clinical evidence summary, the PDQ Cancer Prevention Overview, states that evidence is insufficient to support multivitamin or mineral supplements for cancer prevention.
These are not fringe conclusions. They represent the position of the agencies responsible for guiding cancer prevention policy in the United States, and they draw on the best available trial and cohort data. The NIH Office of Dietary Supplements echoes a similar assessment in its technical fact sheet on multivitamin and multimineral supplements, noting inconsistent and limited evidence of benefit in trials and observational studies. Taken together, the data suggest that for most well-nourished adults, multivitamins are unlikely to move the needle on cancer outcomes.
Gaps in the data and what to watch next
Several questions remain open. The primary trial datasets, including COSMOS and SU.VI.MAX, lack detailed subgroup analyses by baseline diet quality or serum nutrient levels within the multivitamin arms. That means researchers cannot yet say with confidence whether a narrow subset of people with documented deficiencies might benefit differently from supplementation. It is plausible that individuals with very low intake of specific micronutrients could respond differently, but the current evidence base was not designed to test that possibility rigorously.
The observational cohorts provide mortality endpoints over two decades, but they contain no primary records on how supplement formulations changed during that period. A person who started taking a multivitamin in the early 2000s may have been consuming a different product by 2020, and the studies do not account for that variability in dose, ingredient profile, or bioavailability. This limits researchers’ ability to connect any one modern formulation to long-term cancer outcomes.
Real-world adherence is another blind spot. The AHRQ evidence review that underpins the USPSTF recommendation includes detailed methods and risk-of-bias assessments, but it does not directly address how consistently people outside of controlled trial settings actually take their pills. Sporadic use could dilute any effect, positive or negative, making it harder to detect small signals. At the same time, if a supplement needs perfect daily adherence over decades to deliver only a tiny benefit, its practical value for population-level cancer prevention would still be questionable.
Future research may focus less on broad “multivitamin” categories and more on targeted supplementation guided by biomarkers, genetics, or very specific dietary patterns. Large pragmatic trials that stratify participants by baseline nutrient status, or that test simplified formulations aimed at clearly defined deficiencies, could help clarify whether any subgroup meaningfully benefits. For now, however, the dominant message from existing work is that routine multivitamin use in generally healthy adults does not translate into lower cancer risk.
What this means for everyday decisions
For readers who currently take a daily multivitamin primarily to reduce cancer risk, the practical takeaway is straightforward. The strongest available evidence, from randomized trials and large cohorts, indicates that this habit is unlikely to lower the odds of developing cancer or dying from it. That does not mean multivitamins are useless in all contexts: they can help people with medically diagnosed deficiencies, restrictive diets, or conditions that impair nutrient absorption, and they may offer insurance against marginal shortfalls in intake. But as a cancer prevention strategy for otherwise healthy adults, they are not supported by current data.
Deciding whether to continue a multivitamin should involve weighing its modest cost and potential side effects against realistic expectations. For most people, the more impactful cancer-prevention steps remain familiar: avoiding tobacco, limiting alcohol, maintaining a healthy weight, being physically active, following a diet rich in fruits, vegetables, and whole grains, and staying up to date on recommended cancer screenings. These behaviors have far stronger evidence behind them than any over-the-counter multivitamin.
Clinicians can use the emerging consensus to guide conversations with patients who assume that a daily pill offers meaningful protection. Rather than framing multivitamins as harmful or forbidden, the message can be that they are optional for many adults and should not distract from proven lifestyle and screening measures. Patients with specific medical conditions, those who are pregnant or planning pregnancy, and people on certain medications should still discuss supplement use with a health professional, since their needs may differ from those of the general population.
As research continues, recommendations may evolve at the margins, especially for high-risk or nutritionally vulnerable groups. For now, though, the best-supported conclusion is that a standard multivitamin is not a shortcut to lower cancer risk. For most adults, investing energy and resources into evidence-based preventive habits will yield far greater returns than relying on a daily supplement bottle.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
